Skip to main content
PEPTARA LABS
Get Started

PT-141 Research

PT-141 Research: What the Bremelanotide Trials Measured

Published by · Updated · How we research and check our pages

The short answer

PT-141 research comes from two places, clinical trials and one approved label, and both describe the same molecule: bremelanotide. The RECONNECT phase 3 trials were two randomized, placebo-controlled studies in premenopausal women with hypoactive sexual desire disorder, and they gave everyone in the active arm one fixed dose by subcutaneous injection (Kingsberg et al., 2019). The Vyleesi label adds a timing rule and caps on how often it can be used (Vyleesi Prescribing Information). PT-141 is described there as a melanocortin receptor agonist with activity at the MC4R subtype (Vyleesi Prescribing Information). Research-grade PT-141 is not that approved product, and this page gives no dose for anyone.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

What is PT-141, and how does it work?

PT-141, also known as bremelanotide, is a synthetic peptide that the Vyleesi label describes as a melanocortin receptor agonist with activity at the MC4R subtype (Vyleesi Prescribing Information).

It is a synthetic analog of alpha-melanocyte-stimulating hormone. The label notes it activates several melanocortin receptor subtypes, with MC1R and MC4R most relevant at studied dose levels, and adds that the exact mechanism behind its studied effects is not fully established (Vyleesi Prescribing Information). The label's stated indication is for hypoactive sexual desire disorder (HSDD) in premenopausal adults, a persistent lack of sexual desire that causes marked distress (Vyleesi Prescribing Information). Research-grade PT-141 is a separate, non-prescription material and is not that approved product.

What did the RECONNECT bremelanotide trials test?

The RECONNECT phase 3 program tested one fixed dose of bremelanotide, given by subcutaneous injection (Kingsberg et al., 2019).

RECONNECT was two phase 3 randomized controlled trials, both comparing bremelanotide that participants injected themselves under the skin against placebo over a 24-week core phase (Kingsberg et al., 2019). The dose was not raised or lowered during the trials: it was the same for everyone in the active arm. That single-dose design is why PT-141 research centers on one study design rather than a spread of amounts.

What the PT-141 research studied

ParameterWhat the research reportsSource
Trial designTwo randomized, placebo-controlled phase 3 trials with a 24-week core phaseKingsberg et al., 2019
Population studiedPremenopausal women with hypoactive sexual desire disorderKingsberg et al., 2019
Dose designOne fixed amount for everyone in the active arm, not changed over timeKingsberg et al., 2019
RouteSubcutaneous injectionVyleesi Prescribing Information
Most common side effectNausea, about 40 percent (vs about 1 percent placebo)Kingsberg et al., 2019

The table shows how the trials were built and what they found in a controlled study group. It is not a recommendation, a starting point, or a target for any individual.

How often was PT-141 used in the studies?

The Vyleesi label sets firm limits on use, written for prescribers, and this page leaves them out (Kingsberg et al., 2019; Vyleesi Prescribing Information).

PT-141 was not studied as a routine peptide taken on set days. Those caps are not arbitrary: the label ties more frequent use to a risk of focal darkening of the skin, or hyperpigmentation (Vyleesi Prescribing Information). The label also notes that each dose can cause a short-lived rise in blood pressure and a small drop in heart rate for several hours (Vyleesi Prescribing Information).

What side effects did PT-141 research report?

Nausea was the most commonly reported side effect in the phase 3 program, seen in about 40 percent of the bremelanotide group versus about 1 percent on placebo (Kingsberg et al., 2019).

Beyond nausea, the phase 3 trials and the label report flushing, injection site reactions, headache, and vomiting among common adverse reactions, with flushing near 20 percent and headache near 11 percent in the active arm (Kingsberg et al., 2019; Vyleesi Prescribing Information). It also flags transient blood pressure increases after dosing and warns against use in people with uncontrolled high blood pressure or known cardiovascular disease (Vyleesi Prescribing Information). These are label facts about the approved product, not predictions about any research use.

Why does this page leave out the PT-141 trial figure?

The figure is left out because the trial amount belongs to a supervised group of women with HSDD, not to the person reading, so this page leaves it out.

The RECONNECT dose was chosen for premenopausal women who were screened and followed by trial staff, and it says little about anyone outside that group (Kingsberg et al., 2019). The Vyleesi label adds blood pressure and skin-darkening warnings that a prescriber weighs before use (Vyleesi Prescribing Information). Peptara Labs sells PT-141 as research material for lab use, not as Vyleesi. Whether bremelanotide suits a given person is a question for a qualified clinician, not a web page.

Is bremelanotide research different from PT-141 research?

No. Bremelanotide is the generic name for the same molecule PT-141 refers to, so a search for either name leads back to the same trials and the same label (Kingsberg et al., 2019; Vyleesi Prescribing Information).

What differs is the product, not the research. Bremelanotide is the active ingredient in the approved product Vyleesi, which carries a label, an indication, and the use caps described above (Vyleesi Prescribing Information). PT-141 sold as research material is not that approved product, has no label of its own, and carries no approved dose. So the research on this page describes the studied and labeled product, and it reads the same under either name.

How the PT-141 study design differs

PT-141 was studied as one fixed amount given by injection, the same for every participant (Kingsberg et al., 2019).

The two trials shared one protocol, so the authors could pool them. Across both, women on bremelanotide scored 0.35 points higher than placebo on the desire measure and 0.33 points lower on the distress measure. The participants had a mean age of 39, and most were enrolled at U.S. sites (Kingsberg et al., 2019, PMID 31599840).

What did PT-141 research study in women?

The phase 3 research that led to approval was carried out in premenopausal women with hypoactive sexual desire disorder, and every participant in the active arm received the same fixed dose by subcutaneous injection (Kingsberg et al., 2019).

Women are where the PT-141 clinical evidence is concentrated: the RECONNECT program enrolled premenopausal women with HSDD and compared bremelanotide with placebo (Kingsberg et al., 2019). The trials did not scale the amount to body weight and did not change it over time, so what the research describes for women is one trial design, not a separate or sex-specific number. It reports on a studied group, not a recommendation for any individual.

Is PT-141 a nasal spray, and is there anything to calculate?

In the research that led to approval PT-141 was not a nasal spray, and there is no dose to calculate: the phase 3 trials used one fixed subcutaneous injection for everyone (Kingsberg et al., 2019; Vyleesi Prescribing Information).

An intranasal formulation of bremelanotide was explored in earlier development, which is why the nasal-spray question still comes up, but the RECONNECT program and the approved product both settled on subcutaneous injection (Kingsberg et al., 2019; Vyleesi Prescribing Information). The studied route is an injection, not a spray.

Because the studied dose was one fixed amount, with no weight-based scaling and no change over time, there is nothing to calculate for the dose itself (Kingsberg et al., 2019). The math people usually mean by a PT-141 calculator is reconstitution volume, which is a separate step: lyophilized research material has to be reconstituted before any volume is drawn, and our peptide reconstitution calculator works that arithmetic. That is a laboratory-handling reference, not a personal dose.

A PT-141 vial calculator is published on peptidesvietnam.com.

Keep reading

Related research and verification

PT-141 Research: FAQ

Is PT-141 the same as Vyleesi?

Bremelanotide is the active ingredient in the approved product Vyleesi, so the two names point to the same molecule (Vyleesi Prescribing Information). Research-grade PT-141 is sold for laboratory research and is not the approved product.

How did the PT-141 trials set the dose?

The RECONNECT phase 3 trials gave every woman in the active arm the same fixed dose by subcutaneous injection, and the amount never changed during the study (Kingsberg et al., 2019). The figure itself is left off this page.

What does the approved bremelanotide label cover?

The Vyleesi label sets one fixed dose by subcutaneous injection, a timing rule around sexual activity, and caps on how often it can be used (Vyleesi Prescribing Information). Those details belong to the approved product and its prescriber, so they are not repeated here. Bremelanotide and PT-141 name the same molecule, but research-grade PT-141 has no label at all.

Is PT-141 research the same as bremelanotide research?

Yes. Bremelanotide is the generic name for the molecule sold under the research name PT-141, so both terms lead back to the same RECONNECT trials and the same Vyleesi label (Kingsberg et al., 2019; Vyleesi Prescribing Information). The difference is the product: the approved product has a label and an indication, research-grade material has neither.

How was PT-141 given in the studies?

By subcutaneous injection that participants gave themselves (Kingsberg et al., 2019; Vyleesi Prescribing Information).

What is the most common PT-141 side effect in the research?

Nausea, reported in about 40 percent of the active arm versus about 1 percent on placebo in the phase 3 trials (Kingsberg et al., 2019).

Why does the label limit how often PT-141 is used?

The label limits how often bremelanotide can be used because more frequent use is linked to a risk of focal skin darkening, called hyperpigmentation (Vyleesi Prescribing Information).

Can I use this research to set my own PT-141 dose?

No. This page gives no dose figure for that purpose, and any personal decision belongs with a qualified clinician.

Is PT-141 a prescription?

The approved product Vyleesi is prescription-only. Research-grade PT-141 is not a prescription and is sold for research use only.

What did the PT-141 trials study in women?

Women are the only group the phase 3 RECONNECT trials studied: premenopausal women with hypoactive sexual desire disorder (Kingsberg et al., 2019). Every woman in the active arm got the same fixed amount, with no change for body weight, so the research does not describe a separate dose for women. It describes one trial design in one group.

Is PT-141 given as a nasal spray?

No. Both the phase 3 trials and the approved product used a subcutaneous injection, not a nasal spray (Kingsberg et al., 2019; Vyleesi Prescribing Information). An intranasal formulation of bremelanotide was explored in earlier development, but the RECONNECT program and the approved product settled on subcutaneous injection.

Is there a PT-141 calculator?

Not for the dose itself. The trials studied one fixed amount that was not scaled to weight or changed over time, so there is no dose formula to work out (Kingsberg et al., 2019). Reconstitution volume math is a separate step, since lyophilized research material has to be reconstituted before any volume is measured.

References

  1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500. PMID 31599840.
  2. Vyleesi (bremelanotide injection) Prescribing Information. AMAG Pharmaceuticals; FDA-approved label, 2019. U.S. Food and Drug Administration, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us